{"filings":[{"id":443004,"accession_number":"0001193125-26-224080","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-05-14T20:17:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.","Net loss $3.5M vs $2.4M a year ago; cash $12.4M with runway into H2 2027.","Active commercial cancer centers grew to 16 from 8 at year-end 2025; target 36 by year-end 2026.","Phase III TIGeR-PaC enrollment at 106 of 114 patients (93%); full enrollment expected by June 2026.","FY 2026 revenue guidance reaffirmed at $3-4 million."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":563000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105685,"accession_number":"0001493152-26-013653","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx reports 2025 revenue of $1.1M from RenovoCath; net loss $11.2M; cash $13M after $10M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $1.1M vs $43K in 2024; first full year of RenovoCath commercialization; cost of revenue $327K, gross profit $796K.","Net loss $11.2M ($0.32 diluted EPS) vs $8.8M ($0.40) in 2024; R&D spend $6.3M, SG&A $7.0M.","Phase III TIGeR-PaC trial: 104 patients randomized (target 114), 72 deaths; enrollment completion expected mid-2026, final data 2027.","12 U.S. cancer centers actively using RenovoCath as of Feb 2026; 33 centers in pipeline; $400M peak U.S. TAM for device.","Appointed Mark Voll as CFO in Feb 2026; closed $10M private placement (net $9.2M) on Mar 20, 2026; cash $13M on hand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105684,"accession_number":"0001493152-26-013080","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RenovoRx appoints Ramtin Agah, MD as Executive Chairman; $450K salary + bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ramtin Agah, MD appointed Executive Chairman effective Feb 27, 2026; continues as Chief Medical Officer.","$450,000 annual base salary, discretionary bonus up to 40% of base (first bonus payable in 2027 for 2026).","Eligible for annual grants of stock options and other equity awards under Company's 2021 Omnibus Equity Incentive Plan.","Employment at-will; prior consulting agreement replaced; existing Change in Control and Severance Agreement remains in effect.","CEO Shaun Bagai remains principal executive officer; Dr. Agah reports directly to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105683,"accession_number":"0001493152-26-012058","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"RenovoRx raises $10M via common stock and milestone warrants in oversubscribed offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$10M gross from sale of 8.4M shares, 2.2M pre-funded warrants, and 5.3M milestone warrants to 15 investors (including insiders).","Milestone warrants (50% coverage) expire upon $1.5M quarterly product revenue or Mar 30, 2029; exercise price $1.751 (institutional), $1.933 (insiders).","Proceeds to boost RenovoCath commercial rollout and fund Phase III TIGeR-PaC trial to full enrollment by mid-2026.","Insider participation at $1.0288/share vs $0.938 for institutions to comply with Nasdaq pricing rules.","Company must file resale registration within 30 days; liquidated damages of up to 10% of subscription amount if delayed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105682,"accession_number":"0001493152-26-005437","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"RenovoRx appoints Mark Voll as CFO; Kocak resigns as Principal Accounting Officer but remains Controller","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Voll, age 72, appointed CFO effective Feb 4, 2026; also serves as Principal Financial and Accounting Officer.","Ronald B. Kocak resigned as Principal Accounting Officer effective Feb 3, 2026; remains VP and Controller with same salary.","Voll receives $250/hour (50% cash, 50% RSUs) plus initial grant of 60,000 unvested RSUs under 2021 Omnibus Plan.","Voll brings 30+ years finance/accounting experience; led IPOs at Techwell, Montage, Aquantia.","Company generated ~$900K revenue from RenovoCath sales in first nine months of 2025; repeat orders growing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105681,"accession_number":"0001493152-26-000113","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"RenovoRx receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice Dec 31, 2025; closing bid price below $1.00 for 32 consecutive business days.","Has 180 calendar days, until June 30, 2026, to regain compliance by closing at $1.00 for 10 consecutive days.","If non-compliant by June 30, 2026, may qualify for an additional 180-day period with reverse stock split option.","Failure to cure could lead to delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121966,"accession_number":"0001493152-25-023604","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"RenovoRx enters $3.7M ATM equity sales agreement with JonesTrading","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $3,723,029 in common stock may be sold at-the-market through JonesTrading; 3.0% commission.","Shares issued under effective shelf registration S-3 (333-268302) and new prospectus supplement filed Nov 14, 2025.","Company also filed new S-3 to extend current shelf's usability for 180 days past Nov 21, 2025 expiration.","No assurances any shares will be issued; company reimburses agent specified expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121965,"accession_number":"0001493152-25-022325","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx reports Q3 revenue $266K, net loss $2.9M; expands to 14 approved cancer centers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $266K from RenovoCath sales; year-to-date revenue ~$900K from zero prior year.","Net loss $2.9M for Q3 vs $2.5M in Q3 2024; cash $10M as of Sept 30, 2025.","Phase III TIGeR-PaC trial enrollment expected to complete early 2026 with final data in 2027.","Expanded from 5 to 14 approved cancer center customers for RenovoCath since start of 2025.","Hired Philip Stocton as Senior Director of Sales and added two regional sales managers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":885000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138662,"accession_number":"0001641172-25-024147","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx Q2 2025 revenue $422k from RenovoCath; DMC recommends continue Phase III trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $422k from commercial RenovoCath sales, up from $0 in Q2 2024.","Cash $12.3M as of June 30, 2025; net loss $2.9M vs $2.4M YoY.","Independent DMC recommends continue Phase III TIGeR-PaC trial after second interim analysis; 95 patients randomized, 61 events.","13 cancer centers approved as customers (up from 5 in Q1); 4 have used device and placed repeat orders.","Hired Phil Stocton as Senior Director of Sales; launched PanTheR post-marketing registry study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":619000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156116,"accession_number":"0001641172-25-016512","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RenovoRx shareholders elect directors, approve equity plan amendment, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; three directors received >3.2M withheld votes each.","Equity plan amended: 913,794 shares added (2.5% of outstanding); evergreen increased from 3% to 5%.","Ratification of Frank, Rimerman + Co. as auditor for FY2025 passed with 19.13M votes for, 949K against.","Approximately 20.09M shares voted out of 36.55M outstanding, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156115,"accession_number":"0001641172-25-010895","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx Q1 revenue ~$200K from RenovoCath sales; TIGeR-PaC trial 91 patients randomized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue of ~$200K from commercial RenovoCath sales, exceeding internal expectations; gross profit $103K.","Cash $14.6M as of Mar 31, 2025, up from $7.2M at Dec 31, 2024; funds commercial scale-up and trial completion.","Phase III TIGeR-PaC trial: 91 patients randomized, 56 events (second interim analysis triggered); DMC review expected Q3 2025.","Net loss $2.4M vs $1.1M in Q1 2024 due to higher operating costs and lower warrant liability gain.","Management and Board purchased ~143K shares; new U.S. patent issued for TAMP platform (19 patents total)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":197000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156114,"accession_number":"0001641172-25-002009","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx reports first RenovoCath revenue of $43k in Q4 2024; TIGeR-PaC trial 79% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First commercial RenovoCath revenue ~$43k in Q4 2024; sequential growth expected in 2025.","TIGeR-PaC trial: 90 of 114 patients randomized; 50 of 86 events; 2nd interim analysis at 52nd event expected Q2 2025.","Cash $7.2M at 2024 year-end; $10.9M net raised in Feb 2025 public offering.","Net loss $8.8M in 2024 vs $10.2M in 2023; R&D $6.0M, SG&A $5.0M.","Shares outstanding 36.5M as of March 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":197000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174554,"accession_number":"0001493152-25-005559","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"RenovoRx prices $12.1M underwritten public offering of 11.5M shares at $1.05 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11,523,810 shares at $1.05/share; gross proceeds ~$12.1M, net ~$10.9M after underwriting discounts and expenses.","Closing expected February 10, 2025; underwriter warrants issued for 576,191 shares at $1.21/share.","Proceeds to fund Phase III TIGeR-PaC study and commercial activities for RenovoCath device.","Titan Partners Group acted as sole bookrunner for the firm commitment offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191512,"accession_number":"0001493152-24-045373","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q3 2024 net loss $2.5M; cash $9.6M, trial interim analysis targeted late 2024/early 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.5M in Q3 2024 vs $1.4M loss in Q3 2023; R&D flat at $1.7M, G&A down to $1.2M.","Cash $9.6M at Sept 30, sufficient to fund next TIGeR-PaC interim analysis and current RenovoCath commercialization.","Phase III TIGeR-PaC trial in LAPC: next interim analysis triggered by 52nd event (estimated late 2024/early 2025); full enrollment expected H1 2025.","RenovoCath commercialization progressing; increased production with Medical Murray; potential near-term revenue in 2025 via direct or partner channels.","Promoted Robert Strasser to VP R&D & Operations; enrolled first patient at University of Nebraska Medical Center for TIGeR-PaC trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207994,"accession_number":"0001493152-24-038108","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"RenovoRx increases RenovoCath production, expands Medical Murray partnership with warrant for 709,500 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RenovoRx boosts production of FDA-cleared RenovoCath catheter due to strong physician demand; over 500 procedures performed.","New work order with Medical Murray; RenovoRx issues warrant for up to 709,500 shares to incentivize manufacturing milestones.","Phase III TIGeR-PaC trial in pancreatic cancer continues; 52nd event (interim analysis) expected late 2024 or early 2025.","CEO expects commercial launch of RenovoCath as standalone device to generate revenue during 2025; sufficient cash on hand.","Robert Strasser promoted to VP of R&D and Operations to lead manufacturing and commercial strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207993,"accession_number":"0001493152-24-032812","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"RenovoRx appoints Frank Rimerman as auditor effective Aug 12, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Baker Tilly resigned effective Aug 13, 2024 after filing Q2 10-Q.","Audit Committee approved Frank Rimerman engagement on Aug 12, 2024.","No disagreements or reportable events occurred with former auditor.","Frank Rimerman previously served as RenovoRx's auditor for FY 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225520,"accession_number":"0001493152-24-023128","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"RenovoRx enters severance deal with VP/Controller Kocak; annual meeting re-elects six directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Severance provides 50% of base salary on qualifying termination; 100% plus full equity vesting if within 12 months of a change in control.","Kocak also receives 6 months COBRA (12 months in change in control) and pro-rata bonus.","At June 6 annual meeting, all six nominees re-elected: Bagai, Agah, Macfarlane, Marton, Ryan, Spiegel.","Agreement mirrors terms for other RenovoRx executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225519,"accession_number":"0001493152-24-017745","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"RenovoRx auditor Baker Tilly to resign; CEO salary restored with bonuses after $17.2M equity raise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Baker Tilly resigns as auditor effective after Q2 2024 10-Q filing (expected Aug 2024); no accounting disagreements.","Material weakness in internal controls for FY 2023 and 2022; prior going concern opinion noted.","CEO Shaun Bagai salary increased to $520k (from $390k); three other NEOs also received salary restorations.","One-time cash bonuses awarded to NEOs totaling ~$292k, tied to $17.2M equity financing in 2024.","Company expects overall annual executive comp to decrease due to earlier management changes and promotions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}